MedTrace Logo

L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)

NCT01330823 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2011-04-07

No results posted yet for this study

Summary

The study investigated the role of L-Carnitine supplementation on proinflammatory immune response, malnutrition, cancer cachexia and cancer related fatigue in advanced and inoperable pancreatic cancer, UICC Stage IV .

Conditions

  • Pancreatic Carcinoma

Interventions

DIETARY_SUPPLEMENT

L-Carnitine

L-Carnitine, 4g/day, orally (Juice)

DIETARY_SUPPLEMENT

Placebo

tartaric acid same dose like L-Carnitine as placebo

Sponsors & Collaborators

  • University Medicine Greifswald

    lead OTHER

Principal Investigators

  • Markus M. Lerch, Prof. · University Medicine Greifswald

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-10-31
Completion
2010-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01330823 on ClinicalTrials.gov